Holles Natalie C. 4

What Happened

• Natalie C. Holles, a director of Day One Biopharmaceuticals, reported dispositions totaling 273,645 shares on April 23, 2026. The shares and related derivative awards were converted/cancelled in connection with the company’s merger and cash-out at the Merger Consideration of $21.50 per share, representing roughly $5.88 million gross proceeds (subject to withholding and netting).

Key Details

• Transaction date: April 23, 2026 (closing date of the merger).
• Merger purchase price (Merger Consideration): $21.50 per share (F2). Total disposed: 273,645 shares → ≈ $5,883,368 gross.
• Types of dispositions reported: direct share dispositions and multiple derivative-related dispositions (options/RSUs converted/cancelled).
• Post-transaction holdings: following the merger closing, the reporting person no longer holds publicly traded common shares of the company (shares were purchased/converted as part of the merger).
• Relevant footnotes: Merger agreement and closing (F1–F2); all unvested options/RSUs were accelerated to vested immediately prior to the merger and then canceled/converted to cash (F3–F4). Cash amounts paid were net to sellers and subject to applicable withholding taxes.
• Filing/timeliness: Reported with the Form 4 covering the April 23, 2026 transactions (filed same day).

Context

• The multiple "Disposition — Derivative" entries reflect cancellation/conversion of stock options and restricted stock units into the right to receive cash in the merger (for options, typically the cash difference between $21.50 and the exercise price). These are corporate-event driven settlements rather than open-market sales.
• Such merger-related cash-outs are routine in acquisitions and do not necessarily indicate the insider’s ongoing view of the business.